Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.
Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH, Deitelzweig S. Li X, et al. Among authors: nadkarni a. PLoS One. 2018 Jan 26;13(1):e0191722. doi: 10.1371/journal.pone.0191722. eCollection 2018. PLoS One. 2018. PMID: 29373602 Free PMC article.
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L. Amin A, et al. Among authors: nadkarni a. J Manag Care Spec Pharm. 2018 Sep;24(9):911-920. doi: 10.18553/jmcp.2018.24.9.911. J Manag Care Spec Pharm. 2018. PMID: 30156450 Free PMC article. Clinical Trial.
Amin is an employee of the University of California, Irvine, and was a paid consultant to Bristol-Myers Squibb in connection with this study and the development of this manuscript. Keshishian and Zhang are employees of STATinMED Research, a paid consultant to Pfizer …
Amin is an employee of the University of California, Irvine, and was a paid consultant to Bristol-Myers Squibb in connection with thi …
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T. Gupta K, et al. Among authors: nadkarni a. J Manag Care Spec Pharm. 2018 Nov;24(11):1116-1127. doi: 10.18553/jmcp.2018.17488. Epub 2018 Sep 13. J Manag Care Spec Pharm. 2018. PMID: 30212268 Free PMC article.
Dabigatran (HR = 1.17; 95% CI = 0.68-2.03; P = 0.573) was associated with a numerically higher risk of stroke/SE compared with apixaban. ...Dabigatran use was associated with a numerically higher risk of stroke/SE and a significantly higher risk of major blee …
Dabigatran (HR = 1.17; 95% CI = 0.68-2.03; P = 0.573) was associated with a numerically higher risk of stroke/SE compared with apixab …
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Mardekian J, Yuce H, Baker CL. Amin A, et al. Among authors: nadkarni a. J Thromb Thrombolysis. 2019 Aug;48(2):240-249. doi: 10.1007/s11239-019-01838-5. J Thromb Thrombolysis. 2019. PMID: 30924051 Free PMC article.
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves AB, Yuce H, Lip GYH. Deitelzweig S, et al. Among authors: nadkarni a. J Am Geriatr Soc. 2019 Aug;67(8):1662-1671. doi: 10.1111/jgs.15956. Epub 2019 May 21. J Am Geriatr Soc. 2019. PMID: 31112292 Free PMC article.
336 results